Table 2.
Sensitivity analysis of this study.
| Outcomes | N | RR or WMD (95% CI) | I2 | Excluded the studies | N | RR or WMD (95% CI) | I2 |
|---|---|---|---|---|---|---|---|
| ORR | 13 | 1.33 (1.12, 1.59) | 0% | [20, 31] | 11 | 1.23 (1.02, 1.48) | 0% |
| DCR | 12 | 1.17 (1.08, 1.27) | 48% | [20, 31] | 10 | 1.15 (1.05, 1.26) | 51% |
| WBC | 15 | 0.29 (0.20, 0.41) | 0% | [24, 26, 31, 32, 34] | 10 | 0.32 (0.22, 0.48) | 0% |
| HBG | 11 | 0.28 (0.14, 0.54) | 0% | [26, 31, 32, 34] | 7 | 0.28 (0.13, 0.59) | 0% |
| PLT | 15 | 0.31 (0.20, 0.47) | 0% | [24, 26, 31, 32, 34] | 10 | 0.32 (0.20, 0.50) | 0% |
| Vomiting | 12 | 0.27 (0.17, 0.43) | 0% | [24, 31, 32, 34] | 8 | 0.30 (0.17, 0.50) | 0% |
| CD3+ | 6 | 15.09 (11.13, 19.05) | 93% | [20, 27] | 4 | 14.75 (9.33, 20.17) | 88% |
| CD4+ | 6 | 10.25 (7.31, 13.20) | 87% | [20, 27] | 4 | 11.36 (5.76, 16.97) | 83% |
| CD4+/CD8+ | 6 | 0.44 (0.25, 0.63) | 88% | [20, 27] | 4 | 0.38 (0.22, 0.74) | 82% |
Note. WBC, white blood cell; HBG, hemoglobin; PLT, platelet; N, the number of trials.